[go: up one dir, main page]

CO5241355A1 - PACKAGED FORM OF ACTIVE NUCLEOSIDIC PHARMACEUTICAL COMPOSITIONS FOR VACCINES AGAINST HEPATITIS - Google Patents

PACKAGED FORM OF ACTIVE NUCLEOSIDIC PHARMACEUTICAL COMPOSITIONS FOR VACCINES AGAINST HEPATITIS

Info

Publication number
CO5241355A1
CO5241355A1 CO00001261A CO00001261A CO5241355A1 CO 5241355 A1 CO5241355 A1 CO 5241355A1 CO 00001261 A CO00001261 A CO 00001261A CO 00001261 A CO00001261 A CO 00001261A CO 5241355 A1 CO5241355 A1 CO 5241355A1
Authority
CO
Colombia
Prior art keywords
active
packaged form
hepatitis
nucleosidic
against hepatitis
Prior art date
Application number
CO00001261A
Other languages
Spanish (es)
Inventor
Gillian Frances Atkinson
Ronald James Boon
G Vandepapelie Pierre
Anne Cecile Wettendorf Martine
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of CO5241355A1 publication Critical patent/CO5241355A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Forma envasada para una composición farmacéutica que comprende como ingredientes activos: (1) un agente antiviral activo contra el virus de la hepatitis B (2) una vacuna para profilaxis y tratamiento de la hepatitis B, dichos ingredientes de uso simultáneo o secuencial. 1Forma envasada para composición farmacéutica para el tratamiento de pacientes con virus de hepatitis B, dicha composición siendo administrada en forma simultánea o secuencial en cualquier orden de un agente antiviral activo contra el virus de hepatitis B y una vacuna contra la hepatitis B, dichos ingredientes en cantidad segura y eficaz.Packaged form for a pharmaceutical composition comprising as active ingredients: (1) an active antiviral agent against hepatitis B virus (2) a vaccine for prophylaxis and treatment of hepatitis B, said ingredients for simultaneous or sequential use. 1 Packaged form for pharmaceutical composition for the treatment of patients with hepatitis B virus, said composition being administered simultaneously or sequentially in any order of an active antiviral agent against hepatitis B virus and a hepatitis B vaccine, said ingredients in safe and effective amount.

CO00001261A 1999-01-12 2000-01-12 PACKAGED FORM OF ACTIVE NUCLEOSIDIC PHARMACEUTICAL COMPOSITIONS FOR VACCINES AGAINST HEPATITIS CO5241355A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9900630 1999-01-12

Publications (1)

Publication Number Publication Date
CO5241355A1 true CO5241355A1 (en) 2003-01-31

Family

ID=10845878

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00001261A CO5241355A1 (en) 1999-01-12 2000-01-12 PACKAGED FORM OF ACTIVE NUCLEOSIDIC PHARMACEUTICAL COMPOSITIONS FOR VACCINES AGAINST HEPATITIS

Country Status (19)

Country Link
EP (1) EP1140163A2 (en)
JP (1) JP2002534438A (en)
KR (1) KR20010090011A (en)
CN (1) CN1391482A (en)
AR (1) AR022250A1 (en)
AU (1) AU760574B2 (en)
BR (1) BR9916893A (en)
CA (1) CA2359110A1 (en)
CO (1) CO5241355A1 (en)
CZ (1) CZ20012544A3 (en)
HK (1) HK1041434A1 (en)
HU (1) HUP0105070A2 (en)
IL (1) IL144186A0 (en)
NO (1) NO20013337L (en)
NZ (1) NZ512890A (en)
PL (1) PL349347A1 (en)
TR (1) TR200102024T2 (en)
WO (1) WO2000041463A2 (en)
ZA (1) ZA200105690B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL139813A0 (en) 1998-05-22 2002-02-10 Loeb Health Res Inst At The Ot Methods and products for inducing mucosal immunity
CA2337743C (en) 1998-07-31 2015-07-07 Yoshihiro Oka Tumor antigen based on products of the tumor suppressor gene wt1
JP3728439B2 (en) 2001-03-22 2005-12-21 治夫 杉山 WT1 modified peptide
JPWO2003028758A1 (en) * 2001-09-28 2005-01-13 治夫 杉山 Method for inducing antigen-specific T cells
WO2003028757A1 (en) * 2001-09-28 2003-04-10 Haruo Sugiyama Novel method of inducing antigen-specific t cells
TWI275392B (en) * 2002-04-08 2007-03-11 Bristol Myers Squibb Co Low dose liquid entecavir formulations and use
CN101948835A (en) 2002-10-29 2011-01-19 科勒制药集团股份有限公司 The application of CPG oligonucleotide in the treatment infection with hepatitis C virus
JP2006512927A (en) 2002-12-11 2006-04-20 コーリー ファーマシューティカル グループ，インコーポレイテッド 5 'CPG nucleic acids and methods of use thereof
CN100443117C (en) * 2003-05-13 2008-12-17 深圳康泰生物制品股份有限公司 Hepatitis B treating vaccine prepn and its prepn process and use
WO2005121378A2 (en) * 2004-06-03 2005-12-22 Saint Louis University Methods and compositions for vaccination
WO2008104133A1 (en) * 2007-02-28 2008-09-04 Centro De Ingeniería Genética Y Biotecnología Combination therapy for the treatment of chronic hepatitis b
TWI827732B (en) * 2018-12-24 2024-01-01 大陸商遠大賽威信生命科學（南京）有限公司 Pharmaceutical preparations for treating hepatitis B and preparation methods and uses thereof
KR20230157429A (en) * 2021-04-07 2023-11-16 덴카 주식회사 Adjuvant activity enhancers and adjuvant compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0414374T3 (en) * 1989-07-25 1998-03-09 Smithkline Beecham Biolog New antigens and methods for their preparation
CA2324289C (en) * 1998-03-09 2010-07-13 Smithkline Beecham Biologicals S.A. Combined vaccine compositions

Also Published As

Publication number Publication date
HUP0105070A2 (en) 2002-04-29
EP1140163A2 (en) 2001-10-10
PL349347A1 (en) 2002-07-15
AU760574B2 (en) 2003-05-15
BR9916893A (en) 2001-11-20
JP2002534438A (en) 2002-10-15
IL144186A0 (en) 2002-05-23
CA2359110A1 (en) 2000-07-20
WO2000041463A3 (en) 2000-11-09
TR200102024T2 (en) 2001-12-21
KR20010090011A (en) 2001-10-17
CZ20012544A3 (en) 2002-01-16
ZA200105690B (en) 2002-09-25
AR022250A1 (en) 2002-09-04
HK1041434A1 (en) 2002-07-12
CN1391482A (en) 2003-01-15
NO20013337D0 (en) 2001-07-05
WO2000041463A2 (en) 2000-07-20
AU2100900A (en) 2000-08-01
NZ512890A (en) 2003-09-26
NO20013337L (en) 2001-08-17

Similar Documents

Publication Publication Date Title
AR029655A1 (en) IMPROVEMENTS IN FORMULATIONS IN PASTA
BR0108435A (en) Formulation and use of low dose entecavir
AR018410A1 (en) USE OF A COMPOSITION FOR THE MANUFACTURE OF A MEDICINAL PRODUCT USED FOR THE PREVENTION OR TREATMENT OF AN ACUTE STATE OF ASTHMA AND / OR ASTHMA INTERMITENTEY / OR EPISODES OF CHRONIC ASTHMA AND METHOD FOR THE PREVENTION OR TREATMENT OF AN ACUTE STATE OF ASTHMA AND / OR INTERMITTENT ASTHMA AND / OR ASTHON CRON EPISODES
CO5241355A1 (en) PACKAGED FORM OF ACTIVE NUCLEOSIDIC PHARMACEUTICAL COMPOSITIONS FOR VACCINES AGAINST HEPATITIS
UY26724A1 (en) METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUSES
BR0107869A (en) Electrogenated pharmaceutical compositions
ES2167061T3 (en) DOSAGE FORMS TO IMPROVE ERECTILE DYSFUNCTION IN MALE SEX PATIENTS.
MX9202407A (en) PHARMACEUTICAL COMPOSITION CONTAINING AN ALYLAMINE COMPOUND AS THE ACTIVE AGENT AND PROCESS FOR ITS PREPARATION.
BR0008590A (en) Polymeric delivery agent, composition, unit dosage form, method for administering a biologically active agent to an animal requiring the agent, method for preparing a composition; it's composed
ES2156839T1 (en) MEDICINAL CONTAINING ALGINATE AND IMPLANT TO TREAT FIBROSIS.
ECSP045102A (en) Pharmaceutical formulation containing 3- (3-dimethylamino-1-ethyl-2-methyl-propyl) phenol and provides a delayed release of the active ingredient
AR005281A1 (en) ORAL PHARACEUTICAL COMPOSITION, PROCEDURES FOR ITS MANUFACTURE AND USE OF THAT PHARMACEUTICAL COMPOSITION FOR THE PREPARATION OF MEDICINES. .
MX9200992A (en) PHARMACEUTICAL COMPOSITION THAT HAS AS ACTIVE INGREDIENT 3- [2- (DIMETHYLAMINE) ETHYL] -N-METHYL-1H-INDOL-5-METHANOSULFONAMIDE AND PROCEDURE FOR ITS PREPARATION.
AR034900A1 (en) USE OF AN EFFECTIVE AMOUNT OF A PDE4 INHIBITOR AND AN ANTI-POLINERGIC AGENT, WELL IN COMBINED FORM ONLY OR SEPARATELY, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, METHOD TO PREPARE THEM, AND USE OF A COMPOSITION THAT INCLUDES AN EFFECTIVE AMOUNT OF A PDD AN EFFECTIVE AMOUNT
ES2160163T3 (en) PHARMACEUTICAL COMPOSITIONS BASED ON DERIVATIVES OF THE CLASS OF TAXANOS.
AR033688A1 (en) RECONSTITUABLE PARENTERAL COMPOSITION
AR026254A1 (en) THE USE OF A CONTROLLED RELEASE PREPARATION FOR THE PREPARATION OF A MEDICINAL PRODUCT TO INCREASE THE DOSE OR SYSTEM EXPOSURE OF A PHARMACO THAT INHIBITS PHOSPHODESTERASE 4
ES2150404T3 (en) PHARMACEUTICAL COMPOSITIONS OF TIZOXANIDA AND NITOZOXANIDA.
AR045263A1 (en) METHOD, KIT AND PHARMACEUTICAL COMPOSITION TO TREAT VIRAL INFECTIONS
CA2385755A1 (en) Prevention of colorectal cancer
UY26514A1 (en) "COMPOSITION FOR THE TREATMENT OF DAMAGED TISSUES".
UY26595A1 (en) LOW DOSE USE USE FORMULATIONS
ECSP003685A (en) ORAL FORMULATIONS OF CONTROLLED RELEASE
ES2185310T3 (en) HERBAL ANTIVIRICAL AGENT.
AR027287A1 (en) GONADOTROPHIN

Legal Events

Date Code Title Description
FC Application refused